表在性膀胱腫瘍に対する各種抗癌剤単剤投与の効果に関する検討 ： 第2報 ： ヒト表在性膀胱腫瘍の再発予防効果について

Abstract

The purpose of this clinical investigation was to examine prophylactic effects of chemotherapeutic agents after transurethral resection of superficial bladder tumor (TURBt). The first study : A total of 130 evaluable cases were randomized into 3 groups : (1) intravesical instillation of doxorubicin (20 mg/40 ml, 30 mg/30 ml), mitomycin C (20 mg/40 ml), or thiotepa (30 mg/30 ml) ; (2) Non-instillation treatment with etretinate or tegafur ; and (3) controls. All agents were administered for 2 years. Significant suppression of recurrence was observed in stage T1 or grade 2 disease treated with prophylactic instillation administered for the first 24 months of the 48-month observation period. The second study : A total of 140 evaluable cases were randomized into 3 groups : (1) intravesical instillation of thiotepa (30 mg/30 ml) ; (2) oral administration of UFT ; and (3) controls. All agents were administered for 2 years. Significant suppression of recurrence was observed in stage T1, grade 2 or multiple cases with prophylactic instillation of thiotepa for the first 24 months of the 36-month observation period. These 2 studies indicate that bladder instillation therapy of DXR, MMC and thiotepa had some prophylactic effects after TURBt in patients with stage T1, grade 2 and multiple superficial badder cancer.